Safe administration of chemotherapy in mast cell activation syndrome

MP Lythgoe, J Krell, IA McNeish and L Tookman

Abstract

Introduction: Mast Cell Activation Syndrome (MCAS) is an immunogenic disorder typically presenting with episodic multi-organ symptoms, caused by the inappropriate and aberrant release of mast cell mediators. Symptoms may be severe, including anaphylaxis and often occur in response to specific triggers which include many drugs and potentially chemotherapeutic agents. The administration of adjuvant chemotherapy and radiotherapy in endometrial cancer significantly reduces the risk of reoccurrence in patients with high risk disease. Currently there is no evidence or case reports to guide the safe administration of chemotherapy in MCAS patients.

Case report: We present the case of a 59-year-old lady with stage 3 A grade 2 endometroid endometrial cancer who underwent successful surgical management. She then received 4 cycles of adjuvant chemotherapy in the form of carboplatin and paclitaxel. This case describes a staged approach to chemotherapy administration and the utilisation of a carboplatin desensitization regimen to reduce the risk of immediate and delayed hypersensitivity sequelae.

Management & outcome: Utilising an enhanced pre-medication strategy and a staged approach to chemotherapy administration, she was able to complete adjuvant treatment without any serious complications. At the date of censoring (May 2020) she has not shown any evidence of disease re-occurrence.

Discussion & conclusion: Administering chemotherapy to patients with any mast cell disorder remains challenging. We hope that this case may provide the framework for safer chemotherapy administration for any patients at high risk of serious hypersensitivity sequelae in endometrial cancer and beyond.

Keywords
Mast Cell activation syndrome, endometrial cancer, carboplatin, carboplatin desensitization, paclitaxel

Introduction

Mast cell activation disorders (MCAS) are a heterogeneous group of conditions associated with mast cell hyperreactivity and/or proliferation. Patients experience signs and symptoms attributable to inappropriate mast cell activation and pro-inflammatory mediator release. Symptoms range from mild, self-limiting allergic symptoms to potentially life-threatening recurrent anaphylaxis.

Mechanistically, MCAS can be classified as primary, secondary or idiopathic based on biochemical, molecular and clinical factors. In primary MCAS genetic abnormalities, such as mutations in the tyrosine kinase receptor KIT, results in a monoclonal proliferation of mast cells. Secondary MCAS occurs as an indirect result of another disease and/or inflammatory process, most commonly IgE-dependent allergic disease.

Idiopathic MCAS is diagnosed when no primary or secondary causes are identified, despite extensive investigation. Many different drugs including chemotherapeutic agents (including carboplatin and paclitaxel) are known to be potent mast cell stimulators, therefore careful consideration is required before initiating any new procedure or treatment.
Endometrial cancer (EC) is the fourth most common female cancer and the 8th leading cause of cancer-related deaths. Over 70% of endometrial cancers are detected at an early stage (stage 1 or 2) with the remainder being advanced disease with regional (stage 3) or distant (stage 4) metastasis. Surgery is the initial mainstay of management of EC. However, patients with advanced disease (stage 3 or 4) or those with high risk features (clear cell, serous adenocarcinoma or grade 3 invasive endometroid carcinoma) have a greater risk of disease re-occurrence with surgical management alone. Thus, adjuvant treatment to reduce the risk of re-occurrence and extend relapse-free survival is indicated. Chemotherapy and radiotherapy (pelvic and brachytherapy) are the two modalities of treatment which are given in the adjuvant setting. At the time of treatment (January 2018) the standard of care at our institution was a combination of chemotherapy (carboplatin and paclitaxel) followed by radiotherapy (pelvic and/or brachytherapy).

We present a case of how chemotherapy can be pragmatically administered safely to a patient with MCAS at high risk of serious allergic sequelae. There are currently no case reports to guide management in this situation and we hope this may provide a safe framework for other to follow in this unusual circumstance.

**Case report**

A 59-year-old lady presented to her primary care physician (September 2017) with a 4-week history of vaginal bleeding and weight loss. She was referred urgently to a tertiary gynaecology-oncology centre for further investigations. Initial evaluation consisted of blood tests, hysteroscopy and CT imaging of the chest, abdomen and pelvis. Her case was evaluated at the gynaecology oncology multi-disciplinary team (MDT) meeting and a provisional diagnosis of endometroid EC (likely stage 3) was agreed. It was recommended to proceed initially for surgical management.

The patient had a past medical history of hypertension, type 2 diabetes mellitus and most significantly, idiopathic mast cell activation disorder (MCAS) with a persistently raised tryptase. This condition initially presented 7 years ago with recurrent anaphylaxis. A plethora of different triggers have been established including foods (such as chicken, various nuts and seeds) and mast cell triggering drugs such as penicillin and macrolide antibiotics, experiencing both immediate and delayed reactions (up to 48 hours later). This condition was managed at a specialist allergy centre and she took a number of mast cell stabilising/allergy medications including sodium cromoglicate, fexofenadine, ketotifen, montelukast and cetirizine. She also took intermittent short courses of corticosteroid (two courses in past year) following severe reactions. However, despite these measures she continued to experience recurrent anaphylaxis with between two to four life-threatening episodes annually. Patch testing of potential triggers proved inconsistent and unreliable, failing to delineate any definitive triggers.

Recommended surgery consisted of a hysterectomy and salpingo-oophorectomy. Due to her diagnosis of MCAS her operation required meticulous planning, avoiding drugs with proven or theoretical high risk of mast cell activation such as muscle relaxants (e.g. atracurium), anaesthetic drugs (e.g. thiopental) and opioid analgesics (e.g. morphine). The operation proceeded and had no significant complications. She made an excellent recovery and was discharged five days after admission. Following surgery her case was re-discussed at the gynaecology oncology MDT with definitive histology from the operation. Her diagnosis was confirmed as a fully resected (R0 resection) stage IIIA grade 2 endometroid EC with lymphovascular space infiltration. Due to these high risk features she was referred to the oncology team for consideration of adjuvant chemotherapy and radiotherapy.

Currently guidelines for adjuvant treatment in EC recommend between four and six cycles of chemotherapy with carboplatin and paclitaxel followed by radiotherapy. However, in the context of administering chemotherapy in MCAS there are currently no guidelines or case reports to guide management. This patient was reviewed in the oncology clinic and these issues were explored. Due to her higher risk of recurrence she wished to attempt adjuvant chemotherapy to minimise the disease reoccurrence risk.

Liaising with her allergy team, consideration was given to patch test for both carboplatin and paclitaxel, however given the previous unreliability of this test, time scale and the lack of utility for predicting sensitivity to taxanes, this was not deemed appropriate. Taking into account her risk factors for hypersensitivity (MCAS, postmenopausal) it was agreed to proceed cautiously with a staged approach (Table 1) of 4 cycles every 3 weeks of adjuvant chemotherapy (carboplatin and paclitaxel).

The first step to ensure accurate dosing of her chemotherapy (particularly carboplatin) was to estimate her renal function. Therefore, a glomerular filtration rate (GFR) analysis with $^{51}$Cr-ethylenediamine tetra-acetic acid (EDTA) was performed. Mild allergic phenomenon has been reported with administration of $^{51}$Cr-EDTA, however the incidence has not been quantified but is believed to be low. Therefore, as a precautionary measure she was pre-treated with an intravenous antihistamine (chlorpheniramine 10 mg)
thirty minutes before proceeding. This investigation
was completed satisfactorily without incident.

The preferred chemotherapy regimen is currently
carboplatin and paclitaxel given every 3 weeks.

| Cycle 1 | Drug | Route | Dose |
|---------|------|-------|------|
| Day -1: pre-medications (12 hours before) | Dexamethasone | PO | 8 mg |
| Day -1: pre-medications (12 hours before) | Ranitidine | PO | 150 mg |
| Day -1: pre-medications (12 hours before) | Cetirizine | PO | 10 mg |
| Day 1: pre-medications (30 minutes before) | Dexamethasone | IV | 8 mg |
| Day 1: pre-medications (30 minutes before) | Ranitidine | IV | 50 mg |
| Day 1: pre-medications (30 minutes before) | Ondansetron | IV | 8 mg |
| Day 1: pre-medications (30 minutes before) | Chlorpheniramine | IV | 10 mg |
| Day 1: chemotherapy | Carboplatin (AUC 5) | IV | 560 mg |
| Cycle 2 | Drug | Route | Dose |
|---------|------|-------|------|
| Day -1: pre-medications (12 hours before) | Dexamethasone | PO | 8 mg |
| Day -1: pre-medications (12 hours before) | Ranitidine | PO | 150 mg |
| Day -1: pre-medications (12 hours before) | Cetirizine | PO | 10 mg |
| Day 1: pre-medications (30 minutes before) | Dexamethasone | IV | 8 mg |
| Day 1: pre-medications (30 minutes before) | Ranitidine | IV | 50 mg |
| Day 1: pre-medications (30 minutes before) | Ondansetron | IV | 8 mg |
| Day 1: pre-medications (30 minutes before) | Chlorpheniramine | IV | 10 mg |
| Day 1: chemotherapy | Carboplatin (AUC 5) | IV | 560 mg |
| Cycle 3 | Drug | Route | Dose |
|---------|------|-------|------|
| Day -1: pre-medications (12 hours before) | Dexamethasone | PO | 8 mg |
| Day -1: pre-medications (12 hours before) | Ranitidine | PO | 150 mg |
| Day -1: pre-medications (12 hours before) | Cetirizine | PO | 10 mg |
| Day 1: pre-medications (30 minutes before) | Dexamethasone | IV | 8 mg |
| Day 1: pre-medications (30 minutes before) | Ranitidine | IV | 50 mg |
| Day 1: pre-medications (30 minutes before) | Ondansetron | IV | 8 mg |
| Day 1: pre-medications (30 minutes before) | Chlorpheniramine | IV | 10 mg |
| Day 1: chemotherapy | Carboplatin (AUC 5) | IV | 560 mg |
| Cycle 4 | Drug | Route | Dose |
|---------|------|-------|------|
| Day -1: pre-medications (12 hours before) | Dexamethasone | PO | 20 mg |
| Day -1: pre-medications (12 hours before) | Ranitidine | PO | 150 mg |
| Day -1: pre-medications (12 hours before) | Cetirizine | PO | 10 mg |
| Day 1: pre-medications (30 minutes before) | Dexamethasone | IV | 20 mg |
| Day 1: pre-medications (30 minutes before) | Ranitidine | IV | 50 mg |
| Day 1: pre-medications (30 minutes before) | Ondansetron | IV | 8 mg |
| Day 1: pre-medications (30 minutes before) | Chlorpheniramine | IV | 10 mg |
| Day 1: chemotherapy | Carboplatin (AUC 5) | IV | 560 mg |

Note: Patient continued with regular medicines throughout treatment (sodium cromoglicate, fexofenadine, ketotifen, montelukast and cetirizine).

No trials exist comparing the efficacy of either single agent in the adjuvant setting. However, when evaluating the single agent response rate in metastatic EC chemotherapy naïve patients and the hypersensitivity risk
of each drug, it was agreed to initially commence with carboplatin, adding paclitaxel in later cycles if no allergic sequelae or other problems had been encountered.

Traditionally this chemotherapy regimen is given as an outpatient. However, due to her risk of hypersensitivity reactions and having previously experienced both immediate and late-onset severe hypersensitivity reactions to drugs, it was agreed she should receive chemotherapy as an inpatient. To minimise her risk of hypersensitivity sequelae she would also receive pre-medication enhancement drugs and carboplatin as part of a phased 4-step regimen (see Table 2). Phased carboplatin desensitization regimes have been developed to induce short-lived tolerance to facilitate administration in patients who initially developed significant carboplatin hypersensitivity and was deemed appropriate for use in this setting to enhance safety.

The night before her chemotherapy she took oral corticosteroid, antihistamine and H₂ receptor antagonist (in addition to her normal mast cell stabilising medications) before being admitted to hospital on the morning of planned treatment. On admission she had her bloods re-checked for suitability and a physician safety assessment to confirm fitness for treatment. She received pre-medication with intravenous corticosteroid, antihistamine, 5HT₃ receptor antagonist and H₂ receptor antagonist thirty minutes before chemotherapy. The patient's total dose of carboplatin (560 mg) was calculated based on the Calvert formula (see Table 2) with an area-under the curve (AUC) of 5. This was prepared in four increasing concentrations of the total dose: 0.1%, 1%, 10% and standard infusion concentration following a predefined protocol. Each infusion was administered over 30 minutes, except for the highest concentration which was given over 1 hour. Prior to proceeding to the next concentration level, she was examined for signs of hypersensitivity. She completed the treatment without any complications and was observed overnight as an extra-precaution before being discharged.

Following successful treatment without any hypersensitivity sequelae she was reviewed in clinic and considered given to the stage of her treatment. She reported some constitutional symptoms such as fatigue and dry skin, however overall tolerated the treatment well. After careful consideration it was agreed for her next treatment cycle to continue with the carboplatin desensitization regimen and if she continued to tolerate this without complication, to receive paclitaxel the following day. Paclitaxel has a higher risk of immediate hypersensitivity reaction, therefore was given at a slower infusion rate (normally 3 hours) of 6 hours. As per the standard protocol the pre-medication corticosteroid dose (dexamethasone 20 mg) was also increased. She attended for cycle 2, three weeks after her first and received her chemotherapy without incident and was discharged after completing the second infusion.

For the third cycle as she had tolerated both drugs without incident, it was agreed she should continue to receive the drugs as an inpatient on consecutive days. However, as she had not experienced any problems with carboplatin, she should receive this normally (over 1 hour), not via the desensitization protocol and the paclitaxel infusion at the normal rate the next day. This cycle was again completed without any significant adverse events.

For her final cycle she was given carboplatin and paclitaxel on consecutive days as an outpatient but continuing with the enhanced pre-medication. Unfortunately, on the second day during the paclitaxel infusion, she developed a minor hypersensitivity reaction (flushing, back pain). Her infusion was immediately stopped, and she was treated with intravenous hydrocortisone and chlorpheniramine. She responded well to this management and her symptoms stopped following day. Paclitaxel has a higher risk of immediate hypersensitivity reaction, therefore was given at a slower (6 hours) infusion rate.

Management & outcome

Following successful completion of 4 cycles of adjuvant chemotherapy she moved onto the next phase of her treatment. She completed adjuvant radiotherapy in the form of 45 Grey external beam radiotherapy (in 25 fractions) and 8 Grey high dose rate brachytherapy (in 2 fractions).

Table 2. Carboplatin desensitization protocol.

| Infusion   | Concentration of infusion   | Infusion rate                           |
|------------|-----------------------------|-----------------------------------------|
| Infusion 1 | 0.1% of total carboplatin dose* | IV in 100 mls of glucose over 30 minutes |
| Infusion 2 | 1% of total carboplatin dose*  | IV in 100 mls of glucose over 30 minutes |
| Infusion 3 | 10% of total carboplatin dose* | IV in 100 mls of glucose over 30 minutes |
| Infusion 4 | Remainder of carboplatin dose* | IV in 100 mls of glucose over 1 hour    |

Note: Patients should receive pre-medication schedule as outlined in Table 1 (cycle 1).

*aCarboplatin total dose is calculated based on Calvert formula: 5 x (Glomerular Filtration Rate* + 25).

*Glomerular Filtration Rate (GFR) as calculated by ⁵¹Cr-EDTA GFR scan (alternative would be Creatinine Clearance based on Cockcroft-Gault Equation).
This was completed without incident. She has continued on regular follow-up since this time and at the time of censoring (May 2020) has had no evidence of disease re-occurrence.

**Discussion**

Currently there are no recognised protocols to guide safe administration of chemotherapy in patients with MCAS. The combination of carboplatin and paclitaxel chemotherapy agents is an established regime for the adjuvant treatment of endometrial cancer in women with high risk disease.12 The hypersensitivity profiles of paclitaxel and carboplatin differ considerably. Paclitaxel is associated with a higher incidence of hypersensitivity (8-45%).17,18 Reactions typically occur immediately (within 10 minutes) and only 1.3% are severe (grade 3 or 4 reaction).17 Carboplatin has a lower incidence of hypersensitivity; reactions become more frequent with cumulative exposure. In patients receiving up to 6 cycles of chemotherapy the reported incidence is <1%, making this ideal in the adjuvant treatment setting.17,19 However, beyond 6 cycles this rises to 27% and half are classed as moderate or severe reactions.17 Factors pre-disposing patients to hypersensitivity for both agents include any prior history of drug allergies or pre-existing hypersensitivity disorder (including mast cell disorders). Reactions in patients with pre-existing allergic conditions are characteristically more severe in nature and less responsive to pre-medication and treatment strategies. Recent evidence has also demonstrated than concomitant carboplatin and paclitaxel is associated with a higher hypersensitivity risk than alternative carboplatin combination regimens.20

Currently there are no trials evaluating use of single agent chemotherapy in the adjuvant setting for EC. However, information can be gleaned from single agent chemotherapy naïve metastatic EC trials. The most active single agent drugs are platinum agents, taxanes and anthracyclines all producing similar response rates of 20–30%.21 Therefore, when considering a treatment paradigm for this patient, evaluating the hypersensitivity safety profile of carboplatin for 4 cycles and the similar response rates of both drugs, carboplatin was selected as the initial drug of choice.

Desensitization is an allergological procedure primarily utilised to induce a state of temporary tolerance to facilitate essential drug administration. Drug desensitization regimens are typically used when no alternative drug is available and the benefits of such as treatment outweigh potential risks. In this case we utilized a carboplatin desensitization regimen to facilitate safer chemotherapy administration to a patient deemed to be at extremely high risk of developing both immediate and delayed life threatening allergic sequelae. This is the first reported use of this methodology and we hope this may be suitable in other high-risk cases. This approach did allow successful administration, however required significant additional healthcare resources (inpatient admission, special pharmacy chemotherapy preparation) to facilitate treatment.

Systemic mast cell activation diseases (such as systemic mastocytosis) have an associated increased risk of solid cancers including melanoma and non-melanoma skin cancers.22 In MCAS the cancer association risk is less well-defined, however registry studies have identified significantly increased prevalence of melanoma and cancers of the breast, ovary, cervix uteri, thyroid and lung.23 Taking account of the increasing utility of anti-cancer treatments including chemotherapy and the higher risk of malignancy in patient with mast cell disorders, this is likely to be a situation encountered more frequently in the future, therefore appropriate strategies are required.

**Conclusion**

Administering chemotherapy in any setting to patients with a history of severe hypersensitivity reactions and anaphylaxis can be challenging. This case demonstrates a framework to allow cautious chemotherapy administration in patients at high risk of serious allergic sequelae. We have presented this case in the hope that this can be used in similar setting to facilitate patients with a history of hypersensitivity to receive chemotherapy safely and pragmatically.

**Declaration of Conflicting Interests**

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: **M.L.** has received an educational grant from Bayer; **L.T.** has received honoraria from Tesaro and AstraZeneca, outside the submitted work; **I.M.** has received honoraria from Clovis Oncology, Tesaro, AstraZeneca and Takeda, and has also received grants from AstraZeneca, outside the submitted work; **J.K.** has received honoraria from Clovis Oncology, Tesaro and AstraZeneca, outside the submitted work.

**Ethical approval**

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Informed consent
Informed consent was obtained from the patient included in the case report.

ORCID iD
MP Lythgoe https://orcid.org/0000-0002-8952-7639

References
1. Frieri M, Patel R and Celestin J. Mast cell activation syndrome: a review. Curr Allergy Asthma Rep 2013; 13: 27–32.
2. Akin C. Mast cell activation syndromes. J Allergy Clin Immunol 2017; 140: 349–355.
3. Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 2012; 157: 215–225.
4. Valent P, Akin C and Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. American Society of Hematology 2017; 129: 1420–1427. Vol.
5. Castells M. Drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: the role of desensitizations. Front Immunol 2017; 8: 1472.
6. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87–108.
7. SEER Cancer Statistics Review 1975–2017. SEER Cancer Statistics, https://seer.cancer.gov/archive/csr/1975_2017/ (accessed 27 May 2020).
8. Bernardini MQ, Gien LT, Lau S, et al. Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). Gynecol Oncol 2016; 141: 148–154.
9. Creutzberg CL, van Putten WLJ, Wàrlain-Rodenthiis CC, et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the postoperative radiation therapy in endometrial carcinoma trial. JCO 2004; 22: 1234–1241.
10. de Boer SM, Powell ME, Milesklin L, PORTEC Study Group, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol 2019; 20: 1273–1285.
11. Galaal K, Al Moundhri M, Bryant A, et al. Adjuvant chemotherapy for advanced endometrial cancer. Vol. 2014. Cochrane Database of Systematic Reviews. New Jersey: John Wiley and Sons Ltd, 2014.
12. GE Healthcare Limited. Summary of product characteristics; CHROMIUM (51CR) EDTA 3.7 MBQ/ML solution for injection, www.drugs.com/uk/chromium-51cr-edta-3-7-mbq-ml-solution-for-injection-leaflet.html (accessed 27 May 2020).
13. Makrilà N, Syrigou E, Kaklamanos I, et al. Hypersensitivity reactions associated with platinum anti-neoplastic agents: a systematic review. Metal-Based Drugs 2010; 2010: 1–11.
14. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748–1756.
15. London Cancer Alliance; Carboplatin desensitisation regimen, Royal Marsden Hospital Trust. Local Protocol (London Cancer Alliance) version 1. 2007.
16. Li Q, Cohn D, Waller A, et al. Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin. Gynecol Oncol 2014; 135: 90–94.
17. Boulanger J, Bouriquot JAN, Courmoyr G, et al. Management of hypersensitivity to platinum- and taxane-based chemotherapy: CEPO review and clinical recommendations. Curr Oncol 2014; 21: 630.
18. Markman M, Kennedy A, Webster K, et al. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland clinic cancer center. J Clin Oncol 2000; 18: 102–105.
19. Fleming GF. Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J Clin Oncol 2007; 25: 2983–2990.
20. Broesby-Olsen S, Farkas DK, Vestergaard H, et al. Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: a nationwide population-based study. Am J Hematol 2016; 91: 1069–1075. 1
21. Molderings GJ, Zienkiewicz T, Homann J, et al. Risk of solid cancer in patients with mast cell activation syndrome: Results from Germany and USA. Fl1000Res 2017; 6: 1889.